Travere Therapeutics (TVTX) Accumulated Depreciation & Amortization (2015 - 2025)

Travere Therapeutics (TVTX) has 11 years of Accumulated Depreciation & Amortization data on file, last reported at $60.7 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 39.46% year-over-year to $60.7 million; the trailing twelve-month figure through Dec 2025 stood at $60.7 million (up 39.46% YoY), and the FY2025 full-year result was $60.7 million, up 39.46% from the prior year.
• Accumulated Depreciation & Amortization for Q4 2025 stood at $60.7 million, up from $43.6 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $60.7 million in Q4 2025 and bottomed at $12.7 million in Q4 2021.
• The 5-year median for Accumulated Depreciation & Amortization is $38.5 million (2023), against an average of $35.3 million.
• The widest annual swing landed in 2021, when Accumulated Depreciation & Amortization plunged 48.14%; it then jumped 85.96% in 2023.
• A 5-year view of Accumulated Depreciation & Amortization shows it stood at $12.7 million in 2021, then soared by 62.55% to $20.7 million in 2022, then surged by 85.96% to $38.5 million in 2023, then rose by 13.04% to $43.6 million in 2024, then soared by 39.46% to $60.7 million in 2025.
• The last three Accumulated Depreciation & Amortization figures came in at $60.7 million (Q4 2025), $43.6 million (Q4 2024), and $38.5 million (Q4 2023), per Business Quant data.

Peer Comparison